5/2/2013

Lantheus Medical Imaging said the first Phase III trial involving its 18F-flurpiridaz PET agent has cleared a data analysis milestone, and the research will continue. The program comprises two trials involving 1,400 North American and European patients. The agent is being tested in myocardial perfusion imaging of patients believed or known to have coronary artery disease.

Related Summaries